Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin Versus Clopidogrel in Chronic Coronary Syndrome
NCT07572747Phase 3Not yet recruiting
- Start
- Apr 2027
- Primary completion
- Apr 2032
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of clopidogrel in Chronic Coronary Syndrome (CCS) (2 arms). Primary endpoint: Major Adverse Cardiovascular and Cerebrovascular Events at 3 years. Planned start Apr 2027; status: not yet recruiting.
02
Drugs
clopidogrel
03
Conditions
Chronic Coronary Syndrome (CCS)
Beyond the preview
Go deeper on NCT07572747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07572747.